IP Library Granted Patent US 11,248,052
Granted Patent B2
US 11,248,052 · App. 16/282,834 · Granted Feb 15, 2022

Antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor

Inventors: Yang Li (Mountain View, CA); Jennitte LeAnn Stevens (Thousand Oaks, CA); Chadwick Terence King (North Vancouver, CA); Ian Nevin Foltz (Burnaby, CA); Gunasekaran Kannan (Daly City, CA); Junming Yie (Warren, NJ); Shaw-Fen Sylvia Hu (Thousands Oaks, CA)
Assignee: AMGEN INC.
C07K16/2863C07K14/71C07K16/40A61K2039/505C07K2317/21C07K2317/31C07K2317/52C07K2317/56C07K2317/565C07K2317/75C07K2319/00C07K2319/30C12Y302/01031
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,248,052
App. No.
16/282,834
Granted
Feb 15, 2022
Kind
B2
Abstract

The present invention provides compositions and methods relating to or derived from antigen binding proteins capable of inducing β-Klotho, and or FGF21-like mediated signaling. In embodiments, the antigen binding proteins specifically bind to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c.

Claims (5)

1. An isolated antigen binding protein comprising a light chain CDR1 comprising the sequence of SEQ ID NO: 814, a light chain CDR2 comprising the sequence of SEQ ID NO: 894, a light chain CDR3 comprising the sequence of SEQ ID NO: 947, a heavy chain CDR1 comprising the sequence of SEQ ID NO: 603, a heavy chain CDR2 comprising the sequence of SEQ ID NO: 656, and a heavy chain CDR3 comprising the sequence of SEQ ID NO: 733.

2. The antigen binding protein of claim 1 , comprising: a light chain variable domain sequence comprising the sequence of SEQ ID NO: 256 and a heavy chain variable domain sequence comprising the sequence of SEQ ID NO: 354.

3. The antigen binding protein of claim 1 , comprising a light chain comprising the sequence of SEQ ID NO: 52 and a heavy chain comprising the sequence of SEQ ID NO: 151.

4. The antigen binding protein of claim 1 , wherein the antigen binding protein is a humanized antibody, chimeric antibody, a monoclonal antibody, a recombinant antibody, an antigen-binding antibody fragment, a single chain antibody, a diabody, a triabody, a tetrabody, a Fab fragment, an F(fab′) 2 fragment, a domain antibody, an IgD antibody, an IgE antibody, an IgM antibody, an IgG1 antibody, an IgG2 antibody, an IgG3 antibody, an IgG4 antibody, or an IgG4 antibody having at least one mutation in a hinge region.

5. The antigen binding protein of claim 1 , wherein the antigen binding protein comprises one or more non-naturally occurring or encoded amino acids.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 29, 2021
From: LI, YANG; STEVENS, JENNITTE; KING, CHADWICK TERENCE; FOLTZ, IAN; KANNAN, GUNASEKARAN; YIE, JUNMING; HU, SHAW-FEN SYLVIA
To: AMGEN, INC.
Reel/Frame 055756/0861 →
Continuity (6)
Continuation 15400800 · Jan 6, 2017
Division 13487061 · Jun 1, 2012
Provisional Application 61537998 · Sep 22, 2011
Provisional Application 61501133 · Jun 24, 2011
Provisional Application 61493933 · Jun 6, 2011
Related Publication 20190248906A1 · Aug 15, 2019
Cited By (1)
US 12,188,328